Isoyama R, Baba Y, Harada H, Kawai S, Shimizu Y, Fujii M, Fujisawa S, Takihara H, Koshido Y, Sakatoku J
Hinyokika Kiyo. 1986 Aug;32(8):1177-83.
Infertile men (excluding azoospermia) were divided into three groups to test methylcobalamin (CH3-B12) + clomiphene citrate (Clomid) treatment. Group M: CH3-B12 (1,500 micrograms/day, daily for 8 to 60 weeks), Group C: Clomid (25 mg/day for 25 days followed by a 5-day rest period, for 8 to 48 weeks), and Group MC: CH3-B12 + Clomid (CH3-B12: 1,500 micrograms/day, daily and Clomid: 25 mg/day for 25 days followed by a 5-day rest period, for 12 to 24 weeks semen analysis was conducted before and after these administrations. Judging by our criteria, 60.0% (24/40) of the cases in Group M, 71.4%(25/35) in Group C, and 66.7% (8/12) in Group MC were improved. However, in patients whose sperm concentrations were over 10 X 10(6)/ml, 61.9% (13/21) of the cases in Group M, 69.2% (9/13) in Group C, and 80.0% (4/5) in Group MC were improved. Therefore, CH3-B12 + Clomid treatment was successful for patients whose sperm concentrations was over 10 X 10(6)/ml.
不育男性（不包括无精子症患者）被分为三组，以测试甲钴胺（CH3-B12）+枸橼酸氯米芬（克罗米芬）治疗效果。M组：甲钴胺（1500微克/天，持续8至60周）；C组：克罗米芬（25毫克/天，服用25天，随后休息5天，持续8至48周）；MC组：甲钴胺+克罗米芬（甲钴胺：1500微克/天，持续服用，克罗米芬：25毫克/天，服用25天，随后休息5天，持续12至24周）。在这些给药前后进行精液分析。根据我们的标准判断，M组60.0%（24/40）的病例、C组71.4%（25/35）的病例以及MC组66.7%（8/12）的病例病情得到改善。然而，在精子浓度超过10×10⁶/ml的患者中，M组61.9%（13/21）的病例、C组69.2%（9/13）的病例以及MC组80.0%（4/5）的病例病情得到改善。因此，对于精子浓度超过10×10⁶/ml的患者，甲钴胺+克罗米芬治疗取得了成功。
